Kamada Ltd.
KMDA
Positions held
Your positionsKMDA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $448.70M | Enterprise value | $391.74M | Trailing P/E | 20.46 | Forward P/E | 13.48 |
| PEG | 0.59 | Price / book | 1.67 | Beta | 0.13 | Dividend yield | 2.19% |
| Revenue growth | 22.7% | Earnings growth | 23.1% | Gross margin | 40.8% | Operating margin | 17.3% |
| Profit margin | 11.6% | ROE | 8.4% | ROA | 4.6% | Debt / equity | 0.04 |
| Current ratio | 4.06 | Free cash flow | $15.51M | Analyst recommendation | strong_buy | Mean target | $13.50 |
| 52w high | $9.35 | 52w low | $6.55 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $54.9M | $45.2M | $44.7M | $47.0M | $44.8M | — |
| Op margin | 17.3% | 15.4% | 7.9% | 16.6% | 15.8% | — |
| Net income | $9.3M | $4.1M | $3.6M | $5.3M | $7.4M | — |
| Gross margin | 40.9% | 42.3% | 38.0% | 42.0% | 42.3% | — |
| Gross profit | $22.5M | $19.1M | $17.0M | $19.8M | $18.9M | — |
| Operating income | $9.5M | $7.0M | $3.6M | $7.8M | $7.1M | — |
- Revenue +21% vs prior quarter ($55M vs $45M).
- Gross margin 40.9% (was 42.3% prior quarter).
- Operating margin expanded to 17.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $180M | $161M | $143M | $129M | — |
| Op margin | 14.5% | 12.5% | 7.1% | 3.5% | — |
| Net income | $20.2M | $14.5M | $8.3M | -$2.3M | — |
| Gross margin | 42.3% | 43.5% | 38.9% | 36.1% | — |
| Gross profit | $76.4M | $70.0M | $55.5M | $46.7M | — |
| Operating income | $26.2M | $20.1M | $10.1M | $4.5M | — |
Headlines — positive tone
• [OK · fundamentals] Kamada Ltd (KMDA) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
News
2026-10-06 · Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel
2026-10-06 · Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
2026-09-27 · Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
2026-09-17 · Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US
2026-09-10 · Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 · Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
2026-08-19 · Kamada (KMDA) Q2 2026 Earnings Call Transcript
2026-08-14 · Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
2026-08-14 · KMDA or PRTA: Which Is the Better Value Stock Right Now?
2026-08-14 · Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet
Price (daily)
Full chart · RSI · MACD · patterns